---
title: "MYGN: Q2 revenue declined 11% year-over-year, prompting lower 2026 guidance and operational changes"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/294422667.md"
description: "Q2 2026 revenue fell 11% year-over-year to $190.7 million, driven by lower prenatal volumes and payer reimbursement friction, despite strong hereditary cancer and mental health test growth. Guidance for 2026 revenue and gross margin was lowered, and operational initiatives are underway to address reimbursement and efficiency challenges.Based on DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source."
datetime: "2026-07-30T22:12:30.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/294422667.md)
  - [en](https://longbridge.com/en/news/294422667.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/294422667.md)
generator: "portal-rs"
---

# MYGN: Q2 revenue declined 11% year-over-year, prompting lower 2026 guidance and operational changes

Q2 2026 revenue fell 11% year-over-year to $190.7 million, driven by lower prenatal volumes and payer reimbursement friction, despite strong hereditary cancer and mental health test growth. Guidance for 2026 revenue and gross margin was lowered, and operational initiatives are underway to address reimbursement and efficiency challenges.

Based on 

**Disclaimer**

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

### Related Stocks

- [MYGN.US](https://longbridge.com/en/quote/MYGN.US.md)

## Related News & Research

- [Connor Clark & Lunn Investment Management Ltd. Purchases New Position in Myriad Genetics, Inc. $MYGN](https://longbridge.com/en/news/297145267.md)
- [Myriad Genetics to Present at 2026 Wells Fargo Healthcare Conference | MYGN Stock News](https://longbridge.com/en/news/297191868.md)
- [AI turns up a promising finding in cancer data that researchers hadn’t noticed for years](https://longbridge.com/en/news/297215988.md)
- [HAMLET.B: Advanced cancer and infection therapies reached Phase III, supported by strong R&D and financing](https://longbridge.com/en/news/297278926.md)
- [The chips powering AI can take years to design. This startup says AI did it in 2 weeks.](https://longbridge.com/en/news/297153469.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**